Literature DB >> 36029326

Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.

Fenghua Gao1, Tingting Zhang1, Hengqi Liu1, Wei Li1, Xianming Liu1, Lihua Qiu1, Lanfang Li1, Shiyong Zhou1, Zhengzi Qian1, Sitong Dong2, Sai Zhao2, Xianhuo Wang3, Huilai Zhang4.   

Abstract

Progression of disease within 24 months (POD24) is strongly associated with a poor outcome in patients with follicular lymphoma (FL). Our study aimed to identify the potential risk factors for POD24 in patients with FL. Medline, EMBASE and the Cochrane Library were systematically searched from the earliest record to September 2020. Studies investigating the prognostic factors for POD24 in patients with newly diagnosed grade 1-3a FL were included. Among 10,014 pieces of literature, a total of 90 studies investigating 82 risk factors were included for qualitative analysis. Meta-analyses were performed in 31 studies with 11 factors. Results showed that elevated sIL-2R, β2m and LDH, total metabolic tumour volume > 510 cm3, vitamin D < 20 ng/mL, grade 3a and lymphoma-associated macrophages/high-power field ≥ 15 were significantly associated with an increased risk of POD24. No significant association was found between POD24 and the ALC/AMC ratio, sex, T effector signature or EZH2 genetic alteration. Additionally, minimal residual disease, Ki-67, PD-1 and TP53 were analysed narratively. Overall, this is the first study that comprehensively analysed the prognostic factors associated with POD24 in FL patients. We have confirmed the significance value of several common prognostic factors as well as others not commonly included in clinical study, helping to construct an integrated and more efficient model.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Follicular lymphoma; Meta-analysis; POD24; Risk factors; Systematic review

Mesh:

Substances:

Year:  2022        PMID: 36029326     DOI: 10.1007/s00277-022-04914-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   4.030


  33 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.

Authors:  Clara Sortais; Anne Lok; Benoit Tessoulin; Thomas Gastinne; Béatrice Mahé; Viviane Dubruille; Nicolas Blin; Cyrille Touzeau; Anne Moreau; Céline Bossard; Pierre Peterlin; Alice Garnier; Thierry Guillaume; Amandine Le Bourgeois; Patrice Chevallier; Philippe Moreau; Christophe Leux; Steven Le Gouill
Journal:  Ann Hematol       Date:  2020-05-16       Impact factor: 3.673

3.  Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Michelle K Manske; Thomas E Witzig; Anne J Novak; Stephen M Ansell
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

4.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

Review 5.  Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.

Authors:  Tetsuichi Yoshizato; Yasuhito Nannya; Yoichi Imai; Motoshi Ichikawa; Mineo Kurokawa
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-05

6.  Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.

Authors:  Kento Umino; Shin-Ichiro Fujiwara; Shoko Ito; Kiyomi Mashima; Daisuke Minakata; Hirofumi Nakano; Ryoko Yamasaki; Yasufumi Kawasaki; Miyuki Sugimoto; Masahiro Ashizawa; Kaoru Hatano; Kiyoshi Okazuka; Kazuya Sato; Iekuni Oh; Ken Ohmine; Takahiro Suzuki; Kazuo Muroi; Yoshinobu Kanda
Journal:  Leuk Lymphoma       Date:  2016-06-07

7.  Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.

Authors:  Satsuki Murakami; Harumi Kato; Yusuke Higuchi; Kazuhito Yamamoto; Hideyuki Yamamoto; Toko Saito; Hirofumi Taji; Yasushi Yatabe; Shigeo Nakamura; Tomohiro Kinoshita
Journal:  Ann Hematol       Date:  2016-05-25       Impact factor: 3.673

8.  Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.

Authors:  Vít Procházka; Tomáš Papajík; Edgar Faber; Luděk Raida; Zuzana Kapitáňová; Kateřina Langová; Zuzana Prouzová; Marie Jarošová; Karel Indrák
Journal:  Leuk Lymphoma       Date:  2014-02-04

9.  Assessing bias in studies of prognostic factors.

Authors:  Jill A Hayden; Danielle A van der Windt; Jennifer L Cartwright; Pierre Côté; Claire Bombardier
Journal:  Ann Intern Med       Date:  2013-02-19       Impact factor: 25.391

10.  The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.

Authors:  Frederick Lansigan; Ian Barak; Brandelyn Pitcher; Sin-Ho Jung; Bruce D Cheson; Myron Czuczman; Peter Martin; Eric Hsi; Heiko Schöder; Scott Smith; Nancy L Bartlett; John P Leonard; Kristie A Blum
Journal:  Cancer Med       Date:  2018-12-21       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.